245 related articles for article (PubMed ID: 21797806)
1. Ustekinumab in nail psoriasis: an open-label, uncontrolled, nonrandomized study.
Patsatsi A; Kyriakou A; Sotiriadis D
J Dermatolog Treat; 2013 Apr; 24(2):96-100. PubMed ID: 21797806
[TBL] [Abstract][Full Text] [Related]
2. Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1.
Rich P; Bourcier M; Sofen H; Fakharzadeh S; Wasfi Y; Wang Y; Kerkmann U; Ghislain PD; Poulin Y;
Br J Dermatol; 2014 Feb; 170(2):398-407. PubMed ID: 24117389
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of systemic treatment agents on psoriatic nails: a comparative study.
Demirsoy EO; Kıran R; Salman S; Cağlayan C; Aktürk AS; Bayramgurler D; Bilen N
J Drugs Dermatol; 2013 Sep; 12(9):1039-43. PubMed ID: 24002153
[TBL] [Abstract][Full Text] [Related]
4. Comparison of NAPSI and N-NAIL for evaluation of fingernail psoriasis in patients with moderate-to-severe plaque psoriasis treated using ustekinumab.
Kim BR; Yang S; Choi CW; Youn SW
J Dermatolog Treat; 2019 Mar; 30(2):123-128. PubMed ID: 29757042
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of ustekinumab in nail psoriasis and improvement in nail-associated quality of life in a population treated with ustekinumab for cutaneous psoriasis: an open prospective unblinded study.
Rigopoulos D; Gregoriou S; Makris M; Ioannides D
Dermatology; 2011; 223(4):325-9. PubMed ID: 22134046
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).
Papp KA; Langley RG; Lebwohl M; Krueger GG; Szapary P; Yeilding N; Guzzo C; Hsu MC; Wang Y; Li S; Dooley LT; Reich K;
Lancet; 2008 May; 371(9625):1675-84. PubMed ID: 18486740
[TBL] [Abstract][Full Text] [Related]
7. TNF-α antagonists and nail psoriasis: an open, 24-week, prospective cohort study in adult patients with psoriasis.
Saraceno R; Pietroleonardo L; Mazzotta A; Zangrilli A; Bianchi L; Chimenti S
Expert Opin Biol Ther; 2013 Apr; 13(4):469-73. PubMed ID: 23157654
[TBL] [Abstract][Full Text] [Related]
8. Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis.
Langley RG; Rich P; Menter A; Krueger G; Goldblum O; Dutronc Y; Zhu B; Wei H; Cameron GS; Heffernan MP
J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1763-70. PubMed ID: 25693783
[TBL] [Abstract][Full Text] [Related]
9. Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial.
Elewski BE; Okun MM; Papp K; Baker CS; Crowley JJ; Guillet G; Sundaram M; Poulin Y; Gu Y; Geng Z; Williams DA; Rich PA
J Am Acad Dermatol; 2018 Jan; 78(1):90-99.e1. PubMed ID: 28993005
[TBL] [Abstract][Full Text] [Related]
10. Anti-TNF agents and nail psoriasis: a single-center, retrospective, comparative study.
Kyriakou A; Patsatsi A; Sotiriadis D
J Dermatolog Treat; 2013 Jun; 24(3):162-8. PubMed ID: 22136334
[TBL] [Abstract][Full Text] [Related]
11. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
Thaçi D; Blauvelt A; Reich K; Tsai TF; Vanaclocha F; Kingo K; Ziv M; Pinter A; Hugot S; You R; Milutinovic M
J Am Acad Dermatol; 2015 Sep; 73(3):400-9. PubMed ID: 26092291
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).
Leonardi CL; Kimball AB; Papp KA; Yeilding N; Guzzo C; Wang Y; Li S; Dooley LT; Gordon KB;
Lancet; 2008 May; 371(9625):1665-74. PubMed ID: 18486739
[TBL] [Abstract][Full Text] [Related]
13. Nail Psoriasis Does Not Affect Skin Response to Ixekizumab in Patients With Moderate-To-Severe Psoriasis.
Rich P; Goldblum O; Disch D; Lin CY; Merola JF; Elewski B
J Drugs Dermatol; 2020 Aug; 19(8):741-746. PubMed ID: 32845588
[TBL] [Abstract][Full Text] [Related]
14. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
Lebwohl M; Strober B; Menter A; Gordon K; Weglowska J; Puig L; Papp K; Spelman L; Toth D; Kerdel F; Armstrong AW; Stingl G; Kimball AB; Bachelez H; Wu JJ; Crowley J; Langley RG; Blicharski T; Paul C; Lacour JP; Tyring S; Kircik L; Chimenti S; Callis Duffin K; Bagel J; Koo J; Aras G; Li J; Song W; Milmont CE; Shi Y; Erondu N; Klekotka P; Kotzin B; Nirula A
N Engl J Med; 2015 Oct; 373(14):1318-28. PubMed ID: 26422722
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study.
Thaçi D; Unnebrink K; Sundaram M; Sood S; Yamaguchi Y
J Eur Acad Dermatol Venereol; 2015 Feb; 29(2):353-360. PubMed ID: 24846518
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the efficacy of acitretin therapy for nail psoriasis.
Tosti A; Ricotti C; Romanelli P; Cameli N; Piraccini BM
Arch Dermatol; 2009 Mar; 145(3):269-71. PubMed ID: 19289755
[TBL] [Abstract][Full Text] [Related]
17. Ixekizumab Is Effective in Subjects With Moderate to Severe Plaque Psoriasis With Significant Nail Involvement: Results From UNCOVER 3.
Dennehy EB; Zhang L; Amato D; Goldblum O; Rich P
J Drugs Dermatol; 2016 Aug; 15(8):958-61. PubMed ID: 27537996
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study.
Rigopoulos D; Gregoriou S; Stratigos A; Larios G; Korfitis C; Papaioannou D; Antoniou C; Ioannides D
Br J Dermatol; 2008 Aug; 159(2):453-6. PubMed ID: 18565184
[TBL] [Abstract][Full Text] [Related]
19. NAPSI utilization as an evaluation method of nail psoriasis in patients using acitretin.
Mukai MM; Poffo IF; Werner B; Brenner FM; Lima Filho JH
An Bras Dermatol; 2012; 87(2):256-62. PubMed ID: 22570030
[TBL] [Abstract][Full Text] [Related]
20. A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis.
Ortonne JP; Paul C; Berardesca E; Marino V; Gallo G; Brault Y; Germain JM
Br J Dermatol; 2013 May; 168(5):1080-7. PubMed ID: 23013207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]